—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Caris Life Sciences, Inc. Common Stock (CAI) — chart, structure and Closelooknet read

The Closelooknet read

Caris Life Sciences profiles tumours at the molecular level, sequencing DNA, RNA and whole genomes to guide cancer treatment choices. Its platforms cover tissue and blood based tests, including whole exome and whole genome sequencing, early detection and residual disease monitoring tools.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for CAI, from the same nightly bakes the boards use. Research diary readings, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 45/100 · S&P 500 fund at 49, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-03
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 76th percentile of the window, -20.6% over 20 sessions. Factor regime → 2026-11-02
  • Sector × region Health care in US: +2.7% week · +9.9% month · +12.5% quarter · +24.7% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-03
  • Sovereign pressure Index -1.63 · down 2.22 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-02
How it trades on rate days beta 0.99 to TLT · on the worst bond days it moved with the market

How it trades on rate days

How CAI has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.99 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Caris Life Sciences, Inc. Common Stock moved 0.99% on average · correlation 0.14 · higher than 83% of US names
  • Beta, last 3 months 0.51 less rate-sensitive lately than over the year
  • On the 10 worst bond days −0.63% on average against −0.74% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days +1.96% TLT −1.29% that day 2026-09-24

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelooknet universe; scored names rank on their Closelooknet score, the rest on trend state.

Compared against CAI on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Caris Life Sciences, Inc. Common Stock

CAI in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Caris Life Sciences profiles tumours at the molecular level, sequencing DNA, RNA and whole genomes to guide cancer treatment choices. Its platforms cover tissue and blood based tests, including whole exome and whole genome sequencing, early detection and residual disease monitoring tools. It also runs research services for biopharmaceutical companies using the molecular data it generates. The company is based in Irving, Texas, and trades on a US exchange.
Where it sits in the stack
Caris sits outside our index universe for now; it belongs to the healthcare corner of our coverage, in the biotechnology sleeve rather than the chip or infrastructure sleeves the diary tracks for the AI build-out. Its own use of machine learning sits in diagnostics, applying models to sequencing data rather than supplying compute, tools or capacity to the stack.
Who it is priced against
The diary has not placed it in a peer group yet; the comparison the market often draws is with Guardant Health, another company built around molecular profiling in oncology.
Why Closelooknet tracks it
Caris does not hold a seat in any Closelooknet index, and the diary has not built a score for it since coverage only began after its listing. No quotes have run for it in our editions so far.
What the diary watches
The diary watches whether enough trading history builds up for our score and index screens to pick the name up, and whether its early post-listing price swings settle as more quarters of results come through.

Caris Life Sciences, Inc. Common Stock (CAI) trades on US exchanges, classified under Healthcare.

The Closelooknet company score reads 60/100 composite (momentum 93, quality 61, valuation 21) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

The Street on this name 1 analyst action on the wire · latest: price target by BTIG, 2026-10-27

The Street on this name

Analyst actions and the latest print for CAI from the Closelooknet wires — third-party opinions on the record, not our readings.

  • Price target BTIG — target 38 from 33 Target raised to $38 from $33 (+17.1% to spot) 2026-10-27

1 action on the analyst wire since 2026-08-13: 1 target change. Analyst wire → · Earnings wire →

Dividends and capital return no distribution in twelve months · buybacks 113,000 USD in FY2025

Dividends and capital return

What CAI pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Buybacks, FY2025 113,000 USD 0.0% of today's market value
  • Share count +13.8% in FY2025 70 m USD of stock-based compensation in the year
  • Capital returned 113,000 USD · 0% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-04

Quick answers

What is Caris Life Sciences, Inc. Common Stock (CAI)?

Caris Life Sciences, Inc. Common Stock trades as CAI on the US exchange (US) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-04.

Is CAI in a Closelooknet index?

Not currently — Caris Life Sciences, Inc. Common Stock is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-04.

What is Caris Life Sciences, Inc. Common Stock's Closelooknet composite score?

60 out of 100, with momentum 93, quality 61 and valuation 21 sub-scores, as of 2026-11-04. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does CAI trade against its moving averages?

Caris Life Sciences, Inc. Common Stock trades 11.7% above its 50-day and 51.9% above its 200-day moving average (4.1% above its 20-day). As of 2026-11-03 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How does Caris Life Sciences, Inc. Common Stock compare with its peers?

Against its peer group (Biotechnology · US), Caris Life Sciences, Inc. Common Stock (CAI) sits 10.0% below its 52-week high, 11.7% above its 50-day average; Halozyme Therapeutics Inc (HALO) is 4.0% below, BeOne Medicines AG (ONC) is 8.7% below, argenx NV ADR (ARGX) is 16.0% below, as of 2026-11-03. Put any of them next to CAI in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

How does Caris Life Sciences, Inc. Common Stock trade when bond yields rise?

Over the past year Caris Life Sciences, Inc. Common Stock had a beta of 0.99 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 83% of US names. On the 10 sessions in which long bonds fell most it moved −0.63% on average, against −0.74% for the S&P 500. As of 2026-11-03; The "How it trades on rate days" block on this page carries the lines.

What does Caris Life Sciences, Inc. Common Stock do?

Caris Life Sciences profiles tumours at the molecular level, sequencing DNA, RNA and whole genomes to guide cancer treatment choices. Its platforms cover tissue and blood based tests, including whole exome and whole genome sequencing, early detection and residual disease monitoring tools. It also runs research services for biopharmaceutical companies using the molecular data it generates. The diary has not placed it in a peer group yet; the comparison the market often draws is with Guardant Health, another company built around molecular profiling in oncology. (Company snapshot of 2026-09-17.)

Where does Caris Life Sciences, Inc. Common Stock sit in the AI build-out?

Caris sits outside our index universe for now; it belongs to the healthcare corner of our coverage, in the biotechnology sleeve rather than the chip or infrastructure sleeves the diary tracks for the AI build-out. Its own use of machine learning sits in diagnostics, applying models to sequencing data rather than supplying compute, tools or capacity to the stack. Caris does not hold a seat in any Closelooknet index, and the diary has not built a score for it since coverage only began after its listing. No quotes have run for it in our editions so far. (Company snapshot of 2026-09-17.)

Does Caris Life Sciences, Inc. Common Stock pay a dividend?

No cash distribution shows in Caris Life Sciences, Inc. Common Stock’s price series over the last three years. In fiscal 2025 the company bought back 113,000 USD of its own shares, 0% of that year’s free cash flow. The share count rose 13.8% over the fiscal year. As of 2026-11-03; the "Dividends and capital return" block on this page carries the lines.

What has Wall Street done on Caris Life Sciences, Inc. Common Stock recently?

The most recent analyst action on Caris Life Sciences, Inc. Common Stock on the Closelooknet wire is a price target by BTIG on 2026-10-27 (target 38 from 33). 1 action on the analyst wire since 2026-08-13: 1 target change. Analyst actions are third-party opinions recorded by the wire, not Closelooknet readings. The “The Street on this name” block on this page lists the moves; the full feeds are the analyst wire and the earnings wire.

What does this page show?

A live price chart with SMA overlays and drawing tools for CAI, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe

then Biotechnology. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.